Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.

By D. Tracey, Lars Klareskog, E. Sasso, J. Salfeld, P. Tak. Pharmacology and Therapeutics, 2008

1,692 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The safety and side effects of monoclonal antibodies (2010, background): “However, in addition to a range of adverse events that may be generally associated with therapeutic mAbs, there are also adverse effects that are related to the specific target or mechanism of actio”
Therapeutic antibodies for autoimmunity and inflammation (2010, background): “Over the past 12 years, four additional TNF antagonists have been approved by the US Food and Drug Administration (FDA) for human use, each with distinguishing feature”
The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics (2021, background): “Etanercept binds to sTNF-α or tmTNF-α and inactivates them by blocking the interaction with receptors [56].”
Tumour necrosis factor and cancer (2009, background): “This led to the development of antagonists of its action that revolutionized the treatment of rheumatoid arthritis and other inflammatory disease”